Pfizer (PFE) Net Income towards Common Stockholders Growth (1y) (2010 - 2025)
Pfizer (PFE) Net Income towards Common Stockholders Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
14.49% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
- |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
8.81% |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Jun 29, 2025 |
47.06% |
| Sep 29, 2024 |
-166.67% |
| Jun 30, 2024 |
950.00% |
| Mar 31, 2024 |
-600.00% |
| Oct 1, 2023 |
157.14% |
| Jul 2, 2023 |
-105.88% |
| Apr 2, 2023 |
111.11% |
| Oct 2, 2022 |
-61.54% |
| Jul 3, 2022 |
114.41% |
| Apr 3, 2022 |
-1,000.00% |
| Oct 3, 2021 |
-102.32% |
| Jul 4, 2021 |
-126.43% |
| Apr 4, 2021 |
-99.89% |
| Sep 27, 2020 |
13,900.00% |
| Dec 31, 2019 |
-27.38% |
| Sep 29, 2019 |
-63.64% |
| Dec 31, 2018 |
365,800.00% |
| Dec 31, 2017 |
-87.50% |
| Jul 2, 2017 |
100.00% |
| Dec 31, 2016 |
180.00% |
